No Data
No Data
Express News | Editas Medicine Inc: Initiating Cost Savings Measures and Reduction in Headcount to Align Workforce
Express News | Editas Medicine Announces Strategic Transition to in Vivo Gene Editing Company With Intent to Achieve Human Proof of Concept in Approximately Two Years
Editas Medicine Cut to Equal-Weight From Overweight by Wells Fargo
Editas Medicine Analyst Ratings
Wells Fargo Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $4
Wells Fargo Downgrades Editas Medicine(EDIT.US) to Hold Rating, Cuts Target Price to $4